Dataset for: Metabolic Profiling Reveals Reprogramming of Lipid Metabolic Pathways in Treatment of Polycystic Ovary Syndrome with 3-Iodothyronamine

Complex diseases such as polycystic ovary syndrome (PCOS) are associated with intricate pathophysiological, hormonal and metabolic feedbacks that make their early diagnosis challenging, thus increasing the prevalence risks for obesity, cardiovascular and fatty liver diseases. To explore the crosstalk between endocrine and lipid metabolic pathways, we administered 3-Iodothyronamine (T1AM), a natural analog of thyroid hormone, in a mouse model of PCOS and analyzed plasma and tissue extracts using multidisciplinary omics and biochemical approaches. T1AM administration induces a profound tissue specific anti-lipogenic effect in liver and muscle by lowering gene expression of key regulators of lipid metabolism, PTP1B and PLIN2, significantly increasing metabolites (glucogenic amino acids, carnitine and citrate) levels, while enhancing protection against oxidative stress. In contrast, T1AM has an opposing effect on the regulation of estrogenic pathways in the ovary by upregulating STAR, CYP11A1 and CYP17A1. Biochemical measurements provide further evidence of significant reduction of liver cholesterol and triglycerides post T1AM—treatment. Our results shed light onto tissue specific metabolic vs. hormonal pathways interactions, thus illuminating the intricacies within the pathophysiology of PCOS. This study opens up new avenues to design drugs for targeted therapeutics to improve quality of life in complex metabolic diseases.